Neuroendocrine tumors of the pancreas: What's new

Journal of the Pancreas

Volumn 11, Issue 2, 2010, Pages 135-138

  Dimou, Anastasios T ^a   Syrigos, Konstantinos N ^b   Saif, Muhammad Wasif ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE CANCER CENTER   (United States)

Author keywords

Chemoembolization, therapeutic; Everolimus; Ki 67 antigen; mTOR protein; Neuroendocrine tumors; Sunitinib

Indexed keywords

ANTINEOPLASTIC AGENT; CHROMOGRANIN A; DACARBAZINE; EVEROLIMUS; KI 67 ANTIGEN; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; SOMATOSTATIN; STREPTOZOCIN; SUNITINIB; TEMOZOLOMIDE; VASCULOTROPIN;

ADVANCED CANCER; AMINOTRANSFERASE BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER HORMONE THERAPY; CANCER SURGERY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL TRIAL; CONFERENCE PAPER; DECISION MAKING; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; HAND FOOT SYNDROME; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INTERMETHOD COMPARISON; LYMPHOCYTOPENIA; MINIMALLY INVASIVE PROCEDURE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NEUROENDOCRINE TUMOR; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS TUMOR; PROGNOSIS; RETROSPECTIVE STUDY; SIDE EFFECT; THERAPY EFFECT; THROMBOCYTOPENIA; TRIACYLGLYCEROL BLOOD LEVEL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOEMBOLIZATION, THERAPEUTIC; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; CONGRESSES AS TOPIC; GASTROINTESTINAL NEOPLASMS; HUMANS; INDOLES; MEDICAL ONCOLOGY; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PYRROLES; RETROSPECTIVE STUDIES; SIROLIMUS;

EID: 77749285629     PISSN: None     EISSN: 15908577     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (23)

1. Ehehalt F, Saeger HD, Schmidt CM, Grützmann R. Neuroendocrine tumors of the pancreas. Oncologist 2009;14:456-67. [PMID 19411317]
2. Franko J, Feng W, Yip L, Genovese E, Moser AJ. Non-functional neuroendocrine carcinoma of the P pancreas: incidence, tumor biology, and outcomes in 2,158 patients. J Gastrointest Surg 2010; 14:541-8. [PMID 19997980]
3. Halfdanarson TR, Rabe KG, Rubin J, Petersen GM. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol 2008; 19:1727-33. [PMID 18515795]
4. Liu DM, Kennedy A, Turner D, Rose SC, Kee ST, Whiting S, et al. Minimally invasive techniques in management of hepatic neuroendocrine metastatic disease. Am J Clin Oncol 2009; 32:200-15. [PMID 19346815]
5. Hill JS, McPhee JT, McDade TP, Zhou Z, Sullivan ME, Whalen GF, Tseng JF. Pancreatic neuroendocrine tumors: the impact of surgical resection on survival. Cancer 2009; 115:741-51. [PMID 19130464]
6. Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 1992; 326:519-23. [PMID 1310159]
7. Kouvaraki MA, Ajani JA, Hoff P, Wolff R, Evans DB, Lozano R, Yao JC. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 2004; 22:4762-71. [PMID 15570077]
8. Ramanathan RK, Cnaan A, Hahn RG, Carbone PP, Haller DG. Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282. Ann Oncol 2001; 12:1139-43. [PMID 11583197]
9. Arnold R, Müller H, Schade-Brittinger C, Rinke A, Klose K, Barth P, et al. Placebo-controlled, double-blind, prospective, randomized study of the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID study group. ASCO Annual Meeting 2009:Abstracts 4508.
10. Raymond E, Niccoli-Sire P, Bang Y, Borbath I, Lombard-Bohas C,Valle JW, et al. Updated results of the phase III trial of sunitinib (SU) versus placebo (PBO) for treatment of advanced pancreatic neuroendocrine tumors (NET). 2010 ASCO Gastrointestinal Cancers Symposium. Abstract No. 127.
11. Kulke M, Blaszkowsky LS, Zhu AX, Florio S, Regan E, Ryan DP, Chan JA. Phase I/II study of everolimus (RAD001) in combination with temozolomide (TMZ) in patients (pts) with advanced pancreatic neuroendocrine tumors (NET). 2010 ASCO Gastrointestinal Cancers Symposium. Abstract No. 223.
12. Celinski SA, Nguyen KT, Steel JL, Mehra R, Marsh JW, Geller DA, et al. Multimodality management of neuroendocrine tumors metastatic to the liver. 2010 ASCO Gastrointestinal Cancers Symposium. Abstract No. 234.
13. Singh S, Rowsell C, IngbeN, Law C. The role of Ki-67 in the prognosis and management of neuroendocrine (NET) patients in a multidisciplinary cancer center. 2010 ASCO Gastrointestinal Cancers Symposium. Abstract No. 266.
14. Missiaglia E, Dalai I, Barbi S, Beghelli S, Falconi M, della Peruta M, et al. Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J Clin Oncol 2010; 28:245-55. [PMID 19917848]
15. Grozinsky-Glasberg S, Franchi G, Teng M, Leontiou CA, Ribeiro de Oliveira A Jr, Dalino P, et al. Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell Line. Neuroendocrinology 2008; 87:168-81. [PMID 18025810]
16. Zitzmann K, De Toni EN, Brand S, Göke B, Meinecke J, Spöttl G, Meyer HH, Auernhammer CJ. The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells. Neuroendocrinology 2007; 85:54-60. [PMID 17310129]
17. Moreno A, Akcakanat A, Munsell MF, Soni A, Yao JC, Meric-Bernstam F. Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors. Endocr Relat Cancer 2008; 15:257-66. [PMID 18310292]
18. Yao JC, Phan AT, Chang DZ, Wolff RA, Hess K, Gupta S, et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low - to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 2008; 26:4311-8. [PMID 18779618]
19. Yao JC, Lombard-Bohas C, Baudin E, Kvols LK, Rougier P, Ruszniewski P, et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 2010; 28:69-76. [PMID 19933912]
20. Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JEW, Muzikansky A, et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 2006; 24:401-6. [PMID 16421420]
21. La Rosa S, Uccella S, Finzi G, Albarello L, Sessa F, Capella C. Localization of vascular endothelial growth factor and its receptors in digestive endocrine tumors: correlation with microvessel density and clinicopathologic features. Hum Pathol 2003; 34:18-27. [PMID 12605362]
22. Terris B, Scoazec JY, Rubbia L, Bregeaud L, Pepper MS, Ruszniewski P, et al. Expression of vascular endothelial growth factor in digestive neuroendocrine tumours. Histopathology 1998; 32:133-8. [PMID 9543669]
23. Kulke MH, Lenz HJ, Meropol NJ, Posey J, Ryan DP, Picus J, et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 2008; 26:3403-10. [PMID 18612155]